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Abstract Background: Extra-corporeal shock wave lithotripsy (ESWL) is a painful procedure.
Sufficient analgesia is mandatory to achieve good treatment results, as well as patient compliance
and comfort. Dexmedetomidine, owing to its sedative and its analgesic effects, may be suitable
for conscious sedation during ESWL. The aim of this study was to evaluate the use of dexmedeto-
midine compared with propofol for its safety and efficacy during ESWL.
Patients and methods: Fifty-two patients were randomly divided into 2 groups that received either
dexmedetomidine or propofol for elective ESWL. A dose of 1.5 lg/kg of fentanyl was given intra-
venously (IV) to all patients 10 min before the ESWL procedure. In the dexmedetomidine group,
patient received an initial loading dose of 1 lg/kg of dexmedetomidine infused IV over 10 min, fol-
lowed by an infusion rate of 0.3 lg/kg/h. In the propofol group, the initial loading dose of 1 mg/kg
of propofol was infused IV over 10 min, followed by an infusion rate of 3 mg/kg/h. The Observer’s
Assessment of Alertness/Sedation (OOA/S) scores, visual analog scale (VAS), and hemodynamic
and respiratory variables were recorded regularly at 5-min interval during ESWL. Hospital dis-
charge time was determined according to Kortilla’s criteria for outpatient surgeries.
Results: The OOA/S scores in the dexmedetomidine group at the 25- to 45-min assessments were
significantly lower than those seen in the propofol group (P < 0.05). The VAS scores for the
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dexmedetomidine group were significantly lower than those in the propofol group, but only at the
30- to 45-min assessments (P < 0.05). During sedation, the respiratory rate with dexmedetomidine
was significantly slower (P < 0.05). Other clinical variables, adverse effects, and hospital discharge
times were comparable in both groups (P > 0.05).
Conclusion: Dexmedetomidine with fentanyl can be used safely and effectively, and it may be a
valuable alternative to propofol with fentanyl for conscious sedation during ESWL.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
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Even with new-generation lithotripters, extra-corporeal shock
wave lithotripsy (ESWL) is a painful procedure, and sufficient
analgesia is mandatory to achieve good treatment results,
patient compliance and comfort [1]. A combination of a seda-
tive hypnotic and an opioid analgesic is commonly used to
produce patient analgesia and sedation [2,3]. Fentanyl
(Fentanyl–Hameln, 0.1 mg/2 ml) is a potent synthetic narcotic,
has a rapid onset and a short duration of action. It is a strong
agonist at the l-opioid receptors and provides an acceptable
analgesia condition during ESWL but it has a marked
respiratory depressive effect [4]. Propofol (Propofol-Lipuro,
10 mg/ml) is a frequently used sedative hypnotic with minimal
analgesic properties, but it may cause respiratory depression;
an effect that may be potentiated by the presence of opioids
[5,6]. The combination of fentanyl and propofol has shown
to be even more potent analgesic in ESWL with mitigating side
effects such as respiratory depression, decreasing oxygen
saturation, nausea, vomiting, drowsiness, and hypersensitivity
reactions [7,8]. Dexmedetomidine (Precedex, 100 lg/ml) is a
highly selective a-2 adrenergic receptor agonist that has both
analgesic and sedative properties, with minimal effect on
ventilation, and thus may be a valuable drug for use during
outpatient procedures that cause minimal to mild pain, such
as ESWL [9].
This study was designed to compare the sedative, analgesic,
hemodynamic, and respiratory effects of dexmedetomidine
and propofol in combination with fentanyl during ESWL, as
well as the time elapsed to hospital discharge.
2. Patient and methods
This prospective, randomized, double-blinded comparative
clinical study was performed in the Sohag and Qena University
Hospitals of the Sohag and the South Valley Universities,
Egypt respectively, from June 2014 to December 2014. After
approval from the institutional ethical committee of both uni-
versity hospitals, written informed consent was obtained from
each patient. The study sample consists of 52 patients (age
range: 20–60 years).
The inclusion criteria were as follows: Patients with an
American Society of Anesthesiologists (ASA) physical sta-
tus of I or II, and scheduled for ESWL to treat a single
renal (pelvic or upper calyceal) stone with 700–900 Houns-
field Unit (HU) and without pain.
Exclusion criteria included the following: Age younger than
20 years, a history of drug or alcohol abuse, an allergy to
any of the study medications, a second- or third-degree heartblock, chronic use of a2-agonist drugs, and current psychi-
atric or respiratory problems. Patients with urinary tract
infections or obstruction, cysteine stones, coagulopathies,
skeletal deformities, pregnant women and body weights
more than 50% of the ideal body weight were also excluded.
Patients were randomly assigned to receive either
dexmedetomidine with fentanyl or propofol with fentanyl.
Randomization and enrollment were done using sequentially
numbered closed envelopes. All patient assessments were per-
formed by a physician (A.A. Tarik) blinded to the sedation
analgesic technique used during the lithotripsy procedure. To
reduce the selection and the pre-test biases, an anesthetist
(E.I. Darweesh) prepared the study drugs and wrapped the
syringe pumps and tubing with opaque covering.
We performed routine preoperative evaluations and investi-
gations. Upon arrival in the ESWL unit, patients were allowed
to position themselves on lithotripter table, and baseline mea-
surements of mean arterial blood pressure (MAP), heart rate
(HR), respiratory rate (RR), and room air oxygen saturation
(SpO2) were obtained and electrocardiographic (ECG) leads
were applied for continuous ECG monitoring using a Life
Scope monitor (BSM – 2353; Nihon Kohden – Japan). Supple-
mental O2 (4 L/min) was administrated using an oxygen face
mask and, after placement of the intravenous (IV) cannula,
1.5 lg/kg of fentanyl was given to all patients 10 min before
the start of ESWL. Patients were randomly divided into 2
groups: patients in the dexmedetomidine group (D group)
received a loading dose of dexmedetomidine at 1 lg/kg
infused IV over 10 min, followed by a maintenance infusion
of 0.3 lg/kg/h, and patients in the propofol group (P group)
received a loading dose of propofol at 1 mg/kg infused IV over
10 min, followed by a maintenance infusion of 3 mg/kg/h. The
maintenance infusion rate (by syringe pump, B. Braun,
Melsungen AG – Germany) of either dexmedetomidine or
propofol was adjusted to produce a state of moderate
sedation/analgesia formerly called conscious sedation [10].
The ESWL procedure was started at the end of the IV infu-
sion of the loading dose of dexmedetomidine or propofol. All
patients received 3500–4000 shocks (60–80 per min) at 18 kV
using Dornier equipment. Two to 3 min before the end of
the procedure, the drug infusions were discontinued. At the
end of the ESWL procedure, patients were transferred to the
recovery room. Discharge from the hospital was based on
Kortilla’s discharge criteria for outpatient procedures [11].
3. Data collection and measurements
Baseline measurements of HR, non-invasive MAP, RR, and
SpO2 were obtained just prior to the start of the study drug
infusions. The sedation level was evaluated using the modified
Observer’s Assessment of Alertness/Sedation scale (OAA/S),
in which 5, indicates response rapidly to name spoken in normal
tone (awake and alert); 4, lethargic response to name spoken in
normal tone; 3, response only after name is spoken repeatedly
or loudly; 2, response only after mild stimulation or shaking;
and 1, no response to mild stimulation or shaking [12].
The OAA/S scores and hemodynamic (HR and MAP) and
respiratory (RR and SpO2) variables were recorded every
5 min after the baseline measurement until the termination of
the ESWL procedure.
Pain intensity was evaluated on a 100-mm visual analog
scale (VAS) where 0 indicated no pain, and 100, severe pain.
The VAS scores were recorded every 5 min from the start to
the end of the ESWL procedure.
During the procedure, adverse effects caused by excessive
sedation and analgesia, such as hypotension (MAP:
<90 mmHg), bradycardia (HR: <50 beats/min), or oxygen
saturation (SpO2: <92%) were recorded and treated.
For hypotension and bradycardia we used 0.9% saline
infusion, 5 mg of ephedrine and 0.5 mg atropine; for oxygen
saturation issues we used an increased flow of O2
supplementation.
We recorded dose increases due to inadequate sedation and
analgesia in either group, stone disintegration as well as other
adverse effects, such as nausea, vomiting, and dry mouth.
After completion of the ESWL procedure, patients were trans-
ported to the recovery room, where they were observed until
the time they were judged for discharge, according to Kortilla’s
criteria for outpatient procedures [11].
Immediately before discharge from the recovery room,
patients were asked to rate their overall pain experience (0,
no pain; 1, mild pain; 2, moderate pain; or 3, severe pain)
and the degree of their overall satisfaction with the control
of their pain (0, inadequate; 1, fair; 2, good; or 3, excellent).
We recorded the need for analgesic, antiemetic, and/or seda-
tive medications in the recovery room. Post ESWL follow up
was done after 2 weeks using plain X-ray urinary tract and
abdominal ultrasonography.
4. Statistical analysis
Statistical analysis was performed using the Statistical Package
for the Social Sciences (SPSS) version 16.0 (IBM, Chicago, Ill).
The sample size was based on the primary outcome measure-
ment of improved analgesia. An average difference of 15 mm
on a 100-mm VAS was considered clinically relevant [13].
Based on the results of previous studies done by Kaygusuz
et al. [13] it was expected that 95% of the VAS scores would
range between 0 and 80, resulting in a mean ± SD of 47
± 17.7 mm. A sample size of 52 patients (26 in each group)
was calculated to be necessary to detect a 15-mm change in
VAS scores, with a power of 80% and an a error of 5%. Data
are presented as mean ± SD, using number or percentage as
appropriate. The proportions of male/female, ASA physical
status, nausea and vomiting, overall pain experience scores
of 2 and 3, patient satisfaction scores, and time to hospital dis-
charge of the study groups were compared with a v2 test. The
RR, SpO2, HR, MAP, OAA/S and VAS were compared using
repeated-measures analysis of variance (ANOVA), with post
hoc Tukey’s test. Differences were considered to be significant
when the P value was <0.05.
5. Results
The 2 groups were comparable with respect to demographic
data, stone size, ESWL procedure time, and dose increase
due to inadequate sedation and analgesia (Table 1).
The OOA/S scores at 5–20 min were comparable in both
groups (P> 0.05). The OOA/S scores seen in the D group
at 25–45 min were significantly lower than those in the P group
(P< 0.05). In both groups, the OOA/S scores at 5–45 min
were significantly lower than those at the baseline (P< 0.05)
(Fig. 1).
The VAS scores at 10 to 25 min were comparable in both
groups (P> 0.05), but the VAS scores at 30 to 45 min in the
D group were significantly lower than those in the P group
(P< 0.05) (Fig. 2).
The hemodynamic variables of MAP and HR are shown in
Figs. 3 and 4 respectively. The MAP values were significantly
lower at 5 to 45 min when compared with those at baseline in
both groups (P< 0.05). There were no significant differences
in the MAP values between the 2 groups (P> 0.05). Similarly,
the HR values were significantly lower at 5 to 45 min when
compared with those at baseline in both groups (P< 0.05).
There were no significant differences in the HR values between
the 2 groups (P> 0.05). The RR values of the D group were
significantly lower than those in the P group during the seda-
tion period (5–45 min) (P < 0.05) and the RR values during
sedation (5–45 min) were significantly lower than those at
Table 1 Demographic data, stone size, ESWL procedure time, and dose increase due to inadequate sedation and analgesia of the
study groups.
D group (n= 26) P group (n= 26) P value
Age (year) 48 ± 7 46 ± 8 >0.05
Sex (M/F) 16/10 15/11 >0.05
Weight (kg) 85 ± 9 81 ± 11 >0.05
Physical status ASA I/II 22/4 23/3 >0.05
Stone size (mm2) 274 ± 54 268 ± 63 >0.05
ESWL procedure time (min) 44.2 ± 9.6 45.4 ± 6.9 >0.05
Dose increase due to inadequate sedation and analgesia (%) 2 (7.7%) 3 (11.5%) >0.05
Data are presented as mean ± SD, with number or percentage as appropriate.
Abbreviations: ESWL, extra-corporeal shock wave lithotripsy; D group, patients receiving dexmedetomidine; P group, patients receiving
propofol; and ASA, American Society of Anesthesiologists.
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baseline in both groups (P < 0.05) (Fig. 5). The SpO2 values
were similar in both groups (P > 0.05) (Fig. 6).
Adverse effects, such as dry mouth, nausea and vomiting,
and patient overall pain experience scores of 2 and 3 were com-
parable between the 2 study groups (Table 2). With regard to
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Figure 1 Observer’s Assessment of Alertness/Sedation scale
(OAA/S) at baseline and during the extracorporeal shock wave
lithotripsy procedure of the study groups. Data are presented as
mean ± SD. *P< 0.05 vs. the P group. D group, patients
receiving dexmedetomidine, and P group, patients receiving
propofol.
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Figure 2 Visual analog score (VAS) during the extracorporeal
shock wave lithotripsy procedure of the study groups. Data are
presented as mean ± SD. *P< 0.05 vs. the P group. D group,
patients receiving dexmedetomidine, and P group, patients
receiving propofol.
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Figure 3 Mean arterial pressure (MAP) at baseline and during
extracorporeal shock wave lithotripsy procedure of the study
groups. Data are presented as mean ± SD. D group, patients
receiving dexmedetomidine, and P group, patients receiving
propofol.
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Figure 4 Heart rate at baseline and during the extracorporeal
shock wave lithotripsy procedure of the study groups. Data are
presented as mean ± SD. D group, patients receiving dexmedeto-
midine, and P group, patients receiving propofol.
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Figure 5 Respiratory rate at baseline and during the extracor-
poreal shock wave lithotripsy procedure of the study groups. Data
are presented as mean ± SD. *P< 0.05 vs. the P group. D group,
patients receiving dexmedetomidine, and P group, patients
receiving propofol.
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Figure 6 Oxygen saturation at baseline and during the extra-
corporeal shock wave lithotripsy procedure of the study groups.
Data are presented as mean ± SD. D group, patients receiving
dexmedetomidine, and P group, patients receiving propofol.
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patient satisfaction with the sedation method, both methods
were assumed to be good or excellent in more than 80% of
the patients (Table 3). There were no cases of hypotension,
bradycardia, or respiratory depression (RR: <8) reported
for any patient in the 2 study groups. Stones were completely
disintegrated in both groups. Further, no patient required gen-
eral or local anesthesia to complete the ESWL procedure, nor
was the procedure prematurely terminated due to inadequate
sedation or analgesia.
The time to hospital discharge, considered as the time from
the end of the ESWL procedure, was 87.1 ± 27.5 min and 85
± 21.4 min in the D group and P group, respectively
(P > 0.05). Among Kortilla’s hospital discharge criteria [11],
special attention was given to stable vital signs for at least
1 h, no evidence of respiratory depression, patients well-
oriented in time and space, the ability of patients to dress
and walk, and absence of nausea and vomiting. Post ESWL
follow up reported stone clearance occurred in all patients of
the 2 groups.
6. Discussion
Conscious sedation is currently the most commonly used
anesthetic technique for elective ESWL, owing to its high
patient satisfaction level and its short duration of hospital
stay [8]. Alhashemi and Kaki [14] found that dexmedeto-
midine is an effective and safe drug for conscious sedation
during ESWL. Unlike their study evaluating the effects of
dexmedetomidine alone, our study was designed to compare
the effects of dexmedetomidine and propofol in combination
with fentanyl for conscious sedation during ESWL. In this
study, patients in the D group reported slower RR, lower
OOA/S scores, and lower VAS pain scores. These findings
suggest that dexmedetomidine provides advantages over
propofol as a sedative analgesic drug during ESWL. The 2
drugs were similar in terms of their effect on MAP, HR,
overall pain experiences, patient satisfaction scores, adverse
effects, and time to hospital discharge. The results of this
study regarding the analgesic effects of dexmedetomidine
are in agreement with the findings from both animal and
human studies [15–17].
In contrast to the results of our study, Jalowiecki et al. [18]
suggested that the use of dexmedetomidine alone at an initial
loading dose of 1 lg/kg infused IV over 15 min, followed by
an infusion rate of 0.2 lg/kg/h to provide analgesia/sedation
for colonoscopy is limited by its many adverse effects, such
as hemodynamic instability, a prolonged recovery time, ver-
tigo, nausea, vomiting and a complicated administration regi-
men. Supplemental fentanyl was required in 47% of patients to
achieve a satisfactory level of analgesia. Our study differed in
that, for both the D and P groups, we added 1.5 lg/kg of fen-
tanyl intravenously to enhance the analgesic effects of both
drugs. In accordance with our results, Belleville et al. [19]
reported a significant decrease in RR with the use of
dexmedetomidine alone at 1.0, and 2.0 lg/kg IV over 2 min.
Although the RRs decreased in the D group, similar to that
seen by Belleville et al. [19] the SpO2 values did not decrease.
This may be due to the supplemental O2 and the initial dose
of dexmedetomidine given as an infusion and over a longer
time (10 min) in our study. Sedative doses of propofol produce
minimal depressant effects on tidal volume and minute ventila-
tion, with unchanged end-tidal CO2 tension and arterial blood
gases [20]. However, larger doses of propofol can depress the
hypoxic ventilatory response [21] and can cause more frequent
and longer apnea than barbiturates [22]. In this study,
decreases in RR were smaller with propofol than with
dexmedetomidine.
We conclude that conscious sedation with dexmedeto-
midine or propofol in combination with fentanyl for elective
ESWL is practical, effective, and safe, provided that monitor-
ing measures are available, and possible respiratory and circu-
latory complications related to the sedation technique are
promptly treated. Sedative, analgesic, and respiratory vari-
ables were better with dexmedetomidine than with propofol.
Therefore, dexmedetomidine may offer a valuable alternative
to propofol.
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